Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?-Reference-Cited by-同舟云学术

Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?

Published:2017-08 Issue:8 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Le Audrey¹^ORCID,Farmakiotis Dimitrios²,Tarrand Jeffrey J.³,Kontoyiannis Dimitrios P.⁴

Affiliation:

1. Department of Internal Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

2. Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

3. Department of Laboratory Medicine, the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

4. Department of Infectious Diseases, Infection Control and Employee Health, the University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Abstract

ABSTRACT The 28-day crude mortality rate in 68 cancer patients with fluconazole-susceptible dose-dependent Candida glabrata fungemia started on treatment (within 48 h after blood culture collection) with an echinocandin or liposomal amphotericin-B was better (30%) than those treated with azole monotherapy (52%) ( P = 0.07). After adjusting for confounders, azole monotherapy also was associated with worse 28-day survival (hazard ratio, 3.8; P = 0.003).

Funder

Frances King Black Endowment

Rhode Island Foundation Medical Research Award

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00631-17

Reference12 articles.

1. Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations

2. Drug-ResistantCandida glabrataInfection in Cancer Patients